Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer
Status:
Completed
Trial end date:
2020-07-06
Target enrollment:
Participant gender:
Summary
This is a Phase I Study of veliparib (ABT-888) in combination with Gemcitabine and Intensity
Modulated Radiation Therapy in Patients with Locally Advanced, Unresectable Pancreatic
Cancer.
Primary Objectives:
- Determine the maximum tolerable dose of veliparib in combination with gemcitabine and
intensity modulated radiation therapy in patients with locally advanced pancreatic
cancer.
- Determine the safety and toxicity of the combination of veliparib with gemcitabine and
radiation therapy in patients with locally advanced pancreatic cancer